Breast Cancer Survivors Report Improvements in Side Effects After Acupressure

| January 17, 2019

article image
Researchers from the University of Michigan Rogel Cancer Center reported in 2016 that acupressure helped reduce fatigue in breast cancer survivors. In the new study, they looked at the impact of acupressure on symptoms that frequently accompany fatigue in this population: chronic pain, anxiety, depression, and poor sleep. They found acupressure improved all of these symptoms compared with standard care.

Spotlight

Nypro, A Jabil Company

Nypro, A Jabil Company offers customers the widest array of design, engineering, supply chain and manufacturing services in the industry. With over 40 years of experience, our highly specialized teams meet the complex demands of the Medical Device, Diagnostics, Pharmaceutical and Consumer Health markets to enable the world's leading brands to fulfill their market potential.

OTHER ARTICLES

Artificial intelligence in pharma: utilising a valuable resource

Article | March 11, 2020

The pharmaceutical industry is set to greatly benefit from the use of artificial intelligence (AI), due to its wide range of applications. Sydney Tierney discusses how machine learning can enhance marketing, manufacturing and drug trials. Artificial intelligence (AI) can be applied to nearly every aspect of the pharmaceutical and healthcare industry, to enhance data processing. Adopting the technology will reveal the astonishing potential of the healthcare sector, with success rates flying higher than ever before – especially in the research and development of crucial, life-changing drugs.

Read More

Decentralized Clinical Trials: Imperative for Pharma Sector to fight COVID19

Article | March 11, 2020

These are unprecedented times. The world is mobbed by a contagion virus, putting people’s health at risk, threatening to destabilize economies. It has already put global healthcare systems under tremendous pressures, and managed to resist efforts to contain it. Even though coronaviruses are not new, this COVID-19 strain has created panic and forced us to be locked down in our homes sans any movement for weeks, if not months. Organizations are fighting an intense battle to keep their workforce safe, minimize risk, and ensure business continuity. For the Life Sciences industry, however, the challenge is even more significant. The whole world is looking at them to come up with a vaccine and a cure. But that is easier said than done. Bringing a new drug to market is an uphill battle and requires rigorous clinical trials. This process already has regulatory challenges. With the current lockdown situation, the Pharma community is grappled with the challenge of continuing some of the critical and time-sensitive in-flight trials so that their regulatory submission, registration, and market entry are not impacted. But all may not be lost. With the right technology solution, it is possible to turn the situation around rapidly.

Read More

Clinical Supply Availability & Speed to Study Start-Up

Article | March 11, 2020

If you’re part of a clinical study team racing a new product to commercialization, you likely live by these two simple rules: time is money, and the first one to market wins. But just because it’s simple doesn’t mean it’s easy. That ticking clock is background noise to the responsibilities of regulations, study protocols, supply chains, and patient recruitment — all the details that must be worked out before a study can even begin. The pressure is always there. The longer it takes for a study to start, the longer it takes to complete.

Read More

What do you have to lose taking hydroxychloroquine for coronavirus? Potentially your life

Article | March 11, 2020

The president and some of his close advisors — desperate for a COVID-19 cure — are asking “What do you have to lose?” by taking hydroxychloroquine (HCQ), a strong medication never adequately tested for efficacy or safety in COVID-19 patients. The correct answer to the president’s question, which he doesn’t seem to want to hear, is that we have our lives to lose. The president acknowledges “I’m not a doctor” but this raises the question “What do doctors know about the drug recommended by the president? Most doctors are aware that HCQ can be effective for patients with malaria, arthritis or lupus. If they were to follow the president’s suggestion and prescribe it for COVID-19 patients, they would also like to know that it will benefit some of those patients, at least.

Read More

Spotlight

Nypro, A Jabil Company

Nypro, A Jabil Company offers customers the widest array of design, engineering, supply chain and manufacturing services in the industry. With over 40 years of experience, our highly specialized teams meet the complex demands of the Medical Device, Diagnostics, Pharmaceutical and Consumer Health markets to enable the world's leading brands to fulfill their market potential.

Events